Obinutuzumab bulk supplier for pharma manufacturers

Obinutuzumab 25 mg/mL Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 25 mg/mL

Reference Brands: Gazyva (USA), Gazyvaro (EU/UK)

Obinutuzumab is a humanized, glycoengineered monoclonal antibody targeting the CD20 antigen on B-cells. It is used alongside chemotherapy for conditions such as chronic lymphocytic leukaemia (CLL) and follicular lymphoma (FL) to enhance B-cell destruction via immune mediated mechanisms.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Obinutuzumab — third party manufacturing & bulk supply

Obinutuzumab 25 mg/mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Obinutuzumab is supplied as Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Obinutuzumab listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Obinutuzumab →

Back to Listing

Frequently Asked Questions

Obinutuzumab is used to treat certain types of blood cancers, including chronic lymphocytic leukemia (CLL) and follicular lymphoma. It works by targeting the CD20 protein found on the surface of B-lymphocytes, helping the immune system destroy these cancerous cells.

Obinutuzumab is a humanized monoclonal antibody produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. It specifically binds to the CD20 antigen on B-cells, leading to their destruction.

The trade name of Obinutuzumab is Gazyva in the United States and Gazyvaro in the European Union and the United Kingdom.

Obinutuzumab (Gazyva/Gazyvaro) is developed and manufactured by Genentech, a member of the Roche Group.

The generic name is Obinutuzumab.

The brand names are Gazyva and Gazyvaro.

Obinutuzumab is manufactured by Roche and Genentech at facilities in Switzerland, Germany, and the United States under stringent biologic production standards.